Proteostasis Therapeutics
As of the edition of 20 October 2026, Proteostasis Therapeutics runs 3 drugs; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Proteostasis Therapeutics was merged in 2020.
- Proteostasis Therapeutics, Inc.: merged in 2020
Drugs by status
| Status | Count |
|---|---|
| Went quiet | 3 |
| Total | 3 |
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| CFTR Cystic fibrosis transmembrane conductance regulator | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Proteostasis Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.